STAGE III URETER CANCER AJCC V7
Clinical trials for STAGE III URETER CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III URETER CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE III URETER CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo shows promise for tough bladder cancer
Disease control OngoingThis early-phase study tested two immunotherapy drugs (durvalumab and tremelimumab) given before surgery to people with a serious type of bladder cancer that cannot be treated with standard chemotherapy. The main goal was to check safety and side effects. Researchers also looked …
Matched conditions: STAGE III URETER CANCER AJCC V7
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New hope for bladder cancer: immune drug may stop return after surgery
Disease control OngoingThis study tests whether pembrolizumab, an immunotherapy drug that helps the immune system fight cancer, can prevent bladder or urinary tract cancer from returning after surgery. About 739 people with muscle-invasive or locally advanced cancer are randomly assigned to receive the…
Matched conditions: STAGE III URETER CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC